The present study aimed to assess, through a controlled randomized clinical trial (RCT), if the intake of yerba mate can contribute to the improvement of the levels of leptin and PON-1 in individuals affected by overweight or obesity and dyslipidemia, comparing its effects with GT which is already recognized for its cardioprotective benefits. The gene discussed is LEP; the disease is obesity disorder.